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Summary The levels of mRNA for transforming growth factors (TGF alpha and beta) and the epidermal
growth factor receptor (EGFR) were determined in 69 human breast carcinomas and 20 biopsies of non-
neoplastic breast tissue by dot blot hybridisation analysis. TGF alpha mRNA was detected in 42% of cancers
and 44% of non-neoplastic breast tissue at low levels. TGF beta mRNA was found in all breast cancers and
non-neoplastic breast tissues, but the levels of TGF beta mRNA were found to be higher in breast cancers
(P = 0.01). EGFR mRNA was detected in 55% of breast cancers and in all non-neoplastic breast tissue tested.
The presence of EGFR mRNA was inversely related to oestrogen receptor (ER) status (P= 0.0001). Co-
expression of TGF alpha and EGFR was observed in 28% of the carcinomas, and significantly more
commonly in ER negative tumours (P= 0.01). No significant relationship was found between histological
grade, tumour cellularity or tumour desmoplasia and expression of either the TGFs or of EGFR mRNA.
High levels of TGF beta were, however, associated with the absence of lymph node metastases at presentation
(P = 0.05). Levels of TGF alpha and beta and EGFR mRNA were analysed in relationship to the relapse-free
and overall survival of patients with breast cancer, but none was found to predict significantly the outcome in
these patients. Longer clinical follow-up and larger numbers of patients are required to determine whether
TGFs will prove a useful marker for prognosis in breast cancer patients.
Several peptide growth factors are known to be capable of
stimulating the growth of breast cancer cells in vitro. They
include transforming growth factor alpha (TGF alpha) (Salo-
mon et al., 1984), epidermal growth factor (EGF) (Osborne
et al., 1980) and IGF I and II (Salomon & Perroteau, 1986).
TGF beta, on the other hand, inhibits breast cancer cell
proliferation in vitro (Knabbe et al., 1987). Breast cancer cells
in culture have also been shown to secrete a number of
growth factors and to express cell surface receptors for some
of these, such as EGFR. This has led to considerable specu-
lation concerning the association of malignant transform-
ation with the process of autocrine stimulation (Sporn &
Roberts, 1985).
The 50 amino acid peptide, TGF alpha, is known to be
derived from a 160 amino acid precursor molecule and is
capable of binding to the EGF receptor (EGFR) and initia-
ting cell division, as does EGF (Sporn & Roberts, 1985). It
has been reported that TGF alpha synthesis is regulated via
the oestrogen receptor (ER) (Lippman, 1985). To date there
has only been a single report on the occurrence of TGF
alpha transcripts in solid tumours (Derynck et al., 1987).
This showed that a TGF alpha mRNA of 4.5-4.8 kb was
present in many different carcinomas, but only two breast
cancers were studied. These workers failed to find TGF alpha
transcripts in non-malignant adult tissue.
TGF beta is structurally and functionally distinct from
TGF alpha. It is a 25 kDa protein composed of two identical
subunits which have been found to be synthesised by a wide
variety of normal and neoplastic cells (Derynck et al., 1985).
TGF beta mRNA has been detected in many solid tumours.
One such study indicated that the TGF beta mRNA levels in
tumour cells were generally not higher than in actively
dividing normal cells, but these workers did find higher levels
of TGF beta mRNA in the six carcinomas tested when
compared with the adjacent normal tissue (Derynck et al.,
1987).
We have recently investigated the occurrence of growth
factor transcripts in normal breast tissue, benign breast
tumours and breast carcinomas and found that mRNA for
TGF alpha and its receptor, EGFR, occurred together more
commonly in oestrogen independent than in oestrogen depen-
dent carcinomas. We also found that TGF beta mRNA was
more abundant in carcinomas than in benign or normal
breast tissue (Travers et al., 1988).
We have now extended these observations to include a
larger number of breast carcinomas and benign breast sam-
ples, and have examined the expression of transforming
growth factor mRNAs in relation to survival and relapse-free
survival in breast cancer patients.
Materials and methods
Patients and samples
Breast samples were collected at surgery and immediately
frozen and stored in liquid nitrogen for 6-72 months. In this
study we used 69 breast carcinomas (66 primary tumours and
three biopsies of recurrent disease), 20 samples of benign
breast disease (fibroadenoma, 12; mammary dysplasia, eight)
and six samples of normal reduction mammoplasty speci-
mens. In five cases the corresponding axillary lymph node
metastasis was also obtained.
In all cases histological confirmation of diagnosis was
obtained. Of the breast carcinomas, 54/69 (78%) were
infiltrating ductal type, and 9/69 (13%) were lobular cancers.
There were two mucinous and two medullary cancers, one
tubular and one papillary cancer. Wherever possible, details
on histological grade (Bloom & Richardson, 1957), T stage
and nodal status at operation were obtained. In addition,
frozen sections of 37 cancers were assessed for tumour cel-
lularity on an arbitary scale, and the degree of lymphocytic
infiltration was examined in 42 cases. The amount of tumour
stroma (desmoplasia) was also recorded in 36 cases on an
arbitrary scale as: 1, none seen; 2, slight; 3, slight to mod-
erate; 4, moderate; 5, moderate to strong; 6, strong.
Patients were followed up to the end of January 1988. The
time to relapse was defined as the period from primary
surgery until recurrent disease. The site of recurrence was
also noted. Overall survival was defined as the time from
primary surgery to the end of the study. The mean duration
of follow-up was 42.5 months with range 2-115 months.
cDNA probes
The complementary DNA (cDNA) sequences encoding
EGFR (Ullrich et al., 1984), TGF alpha (Derynck et al.,
1984) and TGF betal (Derynck et al., 1985) were excised
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from plasmids and labelled with alpha-32P-dCTP (Amersham,
UK) by the random primer method (Feinberg & Vogelstein,
1983).
Analysis ofRNA
Total cellular RNA was extracted from 0.5-1 g of frozen
tissue as previously described (Chirgwin et al., 1979). In 10
cases, polyadenylated (Poly(A)+) mRNA was obtained by
one passage through oligo (dT) cellulose (Aviv & Leder,
1972). For dot blot analysis serial dilutions of denatured
total RNA were applied to Biodyne A membranes (Pall
Filtration, Portsmouth, UK) using a Bio-Dot apparatus (Bio-
Rad, UK), as previously described (Barrett-Lee et al., 1987).
Also, serial dilutions of the recombinant plasmid being stud-
ied and of non-homologous RNA were applied to each mem-
brane in order to quantify the signal and to determine the
extent of non-specific hybridisation.
For northern analysis (Thomas, 1980), 2.5tsg of poly (A)'
mRNA per sample was resolved in a formaldehyde/agarose
gel and blotted onto Biodyne A membrane. Denatured
RNA/DNA markers were also run to enable sizing of hy-
bridising bands.
Filters were pre-hybridised at 42°C for 6h in 50% (v/v)
deionised formamide, 0.1% sodium dodecyl sulphate (SDS),
5 x Denhardt's solution (1 x Denhardt's solution = 0.02%
each of polyvinylpyrrolidone, bovine serum albumin and
Ficoll), 5 mM EDTA, 0.75 M NaCI and 50 mM NaH2PO4
pH 8.3, and denatured sonicated salmon sperm DNA
(250ggml-').
Filters were then hybridised overnight under the same
conditions as for pre-hybridisation with the addition of
1-5 x 106 c.p.m. ml-' of denatured cDNA probe.
After hybridisation, filters were washed with three changes
of 2 x SSC (20 x SSC = 3 M NaCl, 0.3 M trisodium citrate,
pH7), 0.1% SDS at room temperature, and two changes of
0.1 x SSC, 0.1% SDS at 65'C. Autoradiography was carried
out using Hyperfilm MP (Amersham, UK) with intensifying
screens at - 70°C, for 4-14 days.
Quantification of mRNA was carried out by comparison,
with serial dilutions of the appropriate plasmid. A hybridisa-
tion intensity scale from 1 to 5 was derived corresponding to
7.8-125 pg of plasmid. Allowance was made for the propor-
tion of recombinant insert to vector.
Oestrogen receptor determination
Measurement of ER was by a modification of the dextran-
coated charcoal assay (McGuire & De La Garza, 1973).
When samples were too small for this technique, ER was
estimated by an immunocytochemical assay as previously
described (McClelland et al., 1986).
Using the biochemical assay, carcinomas with
> 10 fmol mg-' were considered ER positive, while with the
immunocytochemical assay, tumours with > 10% staining
were defined as ER positive.
EGFR immunocytochemistry
EGFR protein was visualised using the EGFR1 monoclonal
antibody and the indirect immunoperoxidase technique
(Waterfield et al., 1982). Staining was assessed on a 0, +,
+ +, + + + score corresponding to absent, small numbers,
moderate numbers and large numbers of tumour cells
stained. Intensity of staining was not taken into account.
Statistical analysis
Analysis of data was by x2 test with Yates' continuity correc-
tion. Survival tables were constructed and analysed by the
log rank statistic. Correlations were by Spearman's rank
correlation (rs).
DNA extraction
DNA was extracted from tumours by saving this layer during
the guanidinium/caesium chloride RNA extraction.
Purification was performed using phenol chloroform (1:1)
followed by precipitation with 0.1 volume of 3M sodium
acetate (pH 5.3) and 2.5 volumes of absolute alcohol. DNA
samples were then digested with an excess of EcoR1 restric-
tion enzyme.
Southern analysis
Electrophoresis and blotting on Biodyne A membranes was
carried out as previously described (Southern, 1975). Hy-
bridisation and autoradiography was as for northern
analysis. Samples of normal human lymphocyte DNA were
used as controls.
Results
TGF alpha
TGF alpha mRNA was measured in 66 carcinomas by dot
blot analysis; 28 (42%) contained detectable transcripts. Of
28 TGF alpha positive tumours 18 (64%) were also ER
positive. Of the 38 carcinomas in which no detectable TGF
alpha was found, 27 (71%) were ER positive. In general the
level of TGF alpha mRNA was low, and thus only 'plus' or
'minus' scoring was given. Expression of TGF alpha was
virtually confined to infiltrating ductal carcinomas with the
exception of one medullary carcinoma; all eight lobular car-
cinomas were negative as was one mucinous and one tubular
carcinoma.
In two patients the primary carcinoma and lymph node
metastasis were both assayed. In one case, both tissues were
negative for TGF alpha mRNA and in the other both were
positive. The relationship between TGF alpha mRNA and
tumour grade was examined in 49 carcinomas. Grades 1, 2
and 3 carcinomas were positive for TGF alpha in 3/9 (33%),
8/17 (47%) and 11/23 (48%) respectively, these differences
not being significant (X2 = 0.6, P = 0.74). In the cases where
nodal status was known, 42% of node positive patients and
58% of node negative patients were TGF alpha positive. The
relationship between TGF alpha expression and tumour stro-
ma or desmoplasia was examined but no correlation was seen
(r5 = 0.01, P = 0.94, n = 36).
Four breast carcinoma cell lines were also studied: MCF-7,
T-47D, ZR-75 and MDA-MB-231. The first two exhibited
TGF alpha expression.
Twelve fibroadenomas, seven biopsies from mammary dys-
plasia and six biopsies of histologically confirmed normal
breast were studied. These contained significant levels of
TGF alpha transcript in 4/12, 5/7 and 2/6 cases respectively.
Levels were similar to those found in carcinomas.
Ten unselected breast carcinoma mRNAs were subjected
to northern analysis. The eight positive for TGF alpha con-
tained a 4.8 kb transcript but one cancer also contained a
2.2 kb species (Figure 1). No other mRNAs were seen.
To investigate whether high expression of TGF alpha
mRNA was due to gene amplification or gene rearrangement,
DNA was isolated from five carcinomas, three samples of
mammary dysplasia and three samples of normal breast and
analysed by Southern blotting. None of the carcinomas
showed amplification compared to lymphocyte DNA but one
case of mammary dysplasia showed a 50-100-fold
amplification as did one sample of normal breast tissue
(Figure 2). Figure 2 also shows the absence of a 19 kb band
in a reduction mammoplasty specimen. The reason for this is
not clear and is currently being investigated.
The relationship between the TGF alpha mRNA content
of cancers and the patients' relapse-free survival and overall
survival was also studied. The patient characteristics are
shown in Table I. No association between TGF alpha
mRNA and survival was demonstrated even though the TGF
alpha negative group contained a higher proportion of T2
carcinomas (Table II).A B C D E F
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Figure 1 Northern analysis of TGF and EGFR transcripts.
2.5 jig of Poly(A) + of each sample was resolved on
formaldehyde/agarose gels, blotted onto nylon filters and hybri-
dised to 32P-labelled cDNA probe as described in Materials and
methods. The sizes of the hybridising bands in kilobases are
shown on the right. a, TGF alpha: tracks 1-2 are Poly (A) +
from two human breast cancers. b, TGF beta: tracks a-c are
Poly (A) + from three human breast cancers. c, EGFR: tracks 1,
3 and 4 are Poly (A) + from three human breast cancers, track 2
is Poly (A) + from breast cancer cell line MDA-MB-231.
EGFR
Sixty-four breast cancers were examined for EGFR mRNA
by dot blot analysis. Thirty-five (55%) contained detectable
transcripts for EGFR, the majority of these (85%) being only
of intensity + and + +, with the remainder being + + + or
more. Of the 35 EGFR positive carcinomas 18 (51%) were
ER positive but 26/29 (90%) of the EGFR negative car-
cinomas were ER positive, this difference being highly
significant (P = 0.0001). In contrast, all normal and benign
breast tissues tested contained EGFR message.
No relationship was seen between EGFR mRNA level and
tumour grade in 40 cases since grades 1, 2 and 3 carcinomas
Figure 2 Southern analysis of the TGFa gene. Each 10 iLg
sample of DNA was digested with ECoRl restriction enzyme and
subjected to electrophoresis, southern blotting and hybridisation
to 32P-labelled TGF alpha cDNA as described in Materials and
methods. The sizes of the hybridising fragments in kilobases are
shown on the right. Tracks A and F, reduction mammoplastry
and mammary dysplasia respectively; tracks B-D, three
infiltrating ductal breast cancers; track E, normal human lym-
phocyte DNA.
Table I Characteristics of patients studied
TGF alpha mRNA TGF beta mRNA
Characteristic + ve -ve Low + medium High
T-stage TI 9 4 5 9
T2 10 20 14 15
T3 4 8 3 8
T4 2 2 3 1
N/Kd 3 4 5 2
Nodal
involvement + ve 10 15 13 11
- ve 14 14 8 21
N/K 4 9 9 3
ER status + ve 18 27 20 25
- ve 10 11 10 10
EGFR mRNA + ve 18 17 12 20
- ve 9 20 17 12
N/K I I 1 3
TGF beta mRNAb Low 1 3
Medium 11 15
High 16 20
Total 28 38 30 35
'N/K, not known. bTGF beta mRNA: low = 0 or +,
medium= ++ or +++, high= ++++ or +++++ on
hybridisation intensity scale. This tabledemonstrates thecharacteristics
of the patient's breast carcinomas and relates these to transforming
growth factor mRNA content. Levels of growth factor mRNA
determined as in Materials and methods.
were EGFR positive in 3/7 (43%), 6/14 (43%) and 12/19
(63%) respectively (x2 = 1.65, P = 0.44). Only 1/9 lobular
carcinomas was EGFR positive. All three biopsies of recur-
rent disease studied were EGFR positive.
We had information on nodal status in 42 cases but no
correlation with EGFR mRNA was found (X2 = 025,
P = 0.62). In four patients, EGFR mRNA was measured in
both primary tumour and nodal metastases and in all cases
the levels in both samples were identical.
We also examined the breast carcinoma cell lines for the
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Table II Growth factor expression and relationship to prognosis in breast cancer
Survival Relapse-free survival
Growth factor/receptor No. Obs.a Exp. P value Obs. Exp. P value
TGF alpha mRNA
+ ve 28 7 7.95 0.56 12 15.75
- ve 38 7 6.05 20 16.25 0.17
TGF beta mRNA
Low + medium 30 8 7.98 0.99 19 14.73 0.11
High 35 5 5.02 11 15.27
EGFR mRNA
+ ve 35 6 6.31 0.86 16 16.72 0.79
-ve 29 8 7.69 15 14.28
aObs. = observed number of events; exp. = expected number of events. P values determined from life
tables using the log rank statistic.
presence of EGFR mRNA. MCF-7 and ZR-75 cells were
weakly positive, MDA-MB-231 cells were intensely positive
and T-47D cells were negative.
Three carcinomas, one fibroadenoma and one carcinoma
cell line (MDA-MB-231) were subjected to northern analysis
and, in all cases, three hybridising bands were seen, of 10, 6.4
and 4.8 kb (Figure 1).
To determine whether breast cancers and non-malignant
breast tissue were expressing EGFR protein, an immuno-
cytochemical study using a monoclonal antibody to EGFR
was carried out. Frozen sections from a total of 24 car-
cinomas and three benign fibroadenomas were stained. In
EGFR positive tumours, we observed specific staining of
both the cytoplasm and the plasma membrane of tumour
cells. There was considerable heterogeneity in the pattern of
staining, such that within EGFR positive tumours some in-
dividual cells stained strongly, some weakly, and some had
no staining. This pattern of heterogeneous staining was also
seen in fibroadenomas and in normal breast ducts (Figure
3).
Immunocytochemical staining of EGFR was (as inde-
pendently assessed by a pathologist) found to correlate well
with the presence of EGFR mRNA within the tissues
(X2 = 11.5, P = 0.0007). Only 3/14 cancers expressing EGFR
mRNA showed no antibody staining, while all 10 tumours
with no EGFR message also stained negative for EGFR
protein. All three of the fibroadenomas exhibited both
EGFR mRNA and EGFR staining.
Both EGFR and its ligand, TGF alpha, were expressed
simultaneously in 18/64 (28%) of carcinomas studied and
eight of these were ER positive. Conversely, 20/22 car-
cinomas negative for both proteins were ER positive car-
cinomas (P = 0.01).
In 64 patients detailed clinical follow-up data were avail-
able. These demonstrated no correlation between EGFR
mRNA levels in the primary tumour and the subsequent
relapse rate and overall survival in breast cancer patients
(Table II).
TGF beta
A total of 65 carcinomas and 20 non-malignant breast tissues
were examined for TGF beta mRNA and all contained this
transcript. However, there was a clear difference in the level
of TGF beta transcripts between benign and malignant sam-
ples since 35/65 (54%) of breast carcinomas had high levels
(+ + + + or + + + + +) compared to only 3/20 (15%)
benign samples (X2 = 8.65, P = 0.01). This pattern of TGF
beta expression was not a reflection of the varying degrees of
cellularity of the breast cancers, since in 37 cancers there was
no significant relationship between tumour cellularity and
TGF beta mRNA (r, = 0.3, P = 0.07).
These results contrasted with the pattern seen in breast
cancer cell lines where only MCF-7 cells expressed high levels
of TGF beta mRNA (+ + + +), while the other lines (T-
47D, ZR-75 and MDA-MB-231) contained low or medium
levels (+, + and + + respectively). Interestingly, normal
human lymphocytes were found to contain high levels
(+ + + + +) of TGF beta mRNA.
Figure 3 EGFR immunocytochemistry of normal, benign and
malignant breast tissue. Sections were incubated with the EGFR1
antibody (1:50 dilution) or control antibody and subjected to the
horseradish peroxidase mouse-antihorseradish peroxidase proce-
dure with visualistion by the diaminobenzidine method. Slides
were counter stained with Harris haematoxylin. a, right, infil-
trating ductal breast cancer exhibiting heterogeneous staining of
the cell membranes of tumour cells (original magnific-
ation x 320); left, section from same cancer incubated with con-
trol antibody only (original magnification x 100). b, left, normal
breast duct showing mainly cytoplasmic positive EGFR staining;
right, benign fibroadenoma showing positive staining of the
epithelial component. Note absence of stromal staining.
Since it has been suggested that expression of TGF beta
may be influenced by oestrogen action, the expression of
mRNA for this growth factor was examined in relation to
ER-status in the 65 breast cancers. However, no such rela-
tionship was found in this series (X2 = 3.27, P = 0.19). Also,
there was no correlation between histological grade and
levels of TGF beta message in the 41 breast carcinomas
where this information was available (x2= 3.39, P = 0.49).
Data on nodal status at operation and TGF beta expres-
sion were available in 53 cases. When TGF beta expression
was divided into low, medium and high, a clear relationship
was demonstrated with tumours from node positive patients616 P. BARRETT-LEE et al.
having significantly lower TGF beta mRNA levels compared
to node negative patients (P = 0.05). When TGF beta expres-
sion was examined in relation to histological type, certain
patterns emerged. Thus the nine lobular carcinomas were
found to express significantly lower levels of TGF beta
mRNA compared to 54 non-lobular cancers (x2= 7.16,
P = 0.028).
Since high levels of TGF beta mRNA were found in
normal human lymphocytes, the amount of peritumoral lym-
phocytic infiltration was assessed on frozen sections in 42 of
the breast carcinomas. In eight cancers we observed no lym-
phocytes, in another two there was a very strong reaction,
while the rest showed varying degrees of infiltration. In view
of these findings, TGF beta expression was examined in
relationship to lymphocytic infiltration in these 42 car-
cinomas, but no correlation was found (r, = 0.19, P = 0.22).
Polyadenylated RNA from three carcinomas was analysed
by northern hybridisation. In all cases a TGF beta transcript
of 2.5 kb was found. No other bands were detected (Figure
1).
We examined the influence of tumour TGF beta mRNA
levels on the survival of breast cancer patients. Although
patients with higher levels of tumour TGF beta mRNA had
slightly longer relapse-free survival, this difference was not
significant. Similarly, overall survival was not seen to be
related to TGF beta mRNA levels.
Discussion
This study is principally concerned with determining the
clinical significance of TGF synthesis by human breast
cancers. Previous studies in breast cancer have been, in the
main, limited to a few well-defined breast cancer cell lines
(Lippmann et al., 1986; Bronzert et al., 1987; Peres et al.,
1987). Several groups have postulated a role for these factors
in breast cancer cell proliferation based on in vitro studies.
Very few data have been available on growth factor expres-
sion in non-neoplastic breast tissue.
In view of the fact that these peptides are locally produced
and locally active it was felt important to study mRNAs
encoding these substances, since these would more accurately
reflect synthesis in situ rather than absorption or storage of
peptide. Also there is evidence that, in some cases, growth
factors produced by cancer cells are not secreted, but remain
intracellular or cell-membrane associated (Stoscheck & King,
1986).
Our main observation is that these factors are capable of
being synthesised by all breast tissues: normal, benign and
malignant. TGF alpha mRNA synthesis does not appear to
differ between malignant and non-malignant tissue but TGF
beta mRNA is more abundant in breast cancer tissue when
compared with non-neoplastic breast. Co-existence of both
TGF alpha and its receptor, EGFR, was more often
observed in ER negative breast cancers, and this may signify
a role for this peptide in the oestrogen independent growth of
these tumours. This has already been suggested by the
finding (from both binding studies and immunocytochemis-
try) that EGFR is expressed predominantly in ER negative
breast cancers (Fitzpatrick et al., 1984; Sainsbury et al.,
1985).
None of the growth factors in this study demonstrated a
relationship to either tumour cellularity or histological grade.
This suggests that levels of growth factor mRNA are not
simply related to cellular proliferation or mitotic rate. It has
also been suggested that the desmoplastic reaction seen in
many carcinomas may be due to the production, by tumour
cells, of growth factors mitogenic to stromal cells (Ross et
al., 1986; Peres et al., 1987). However, we have previously
shown that no relationship exists between PDGF expression
and stromal proliferation in human breast cancer biopsies
(Travers et al., 1988). In the present study the same lack of
correlation with tumour desmoplasia was seen for transform-
ing growth factor mRNA expression.
Transforming growth factor expression was found to be
generally low or absent in infiltrating lobular breast cancers.
Most of these tumours were also EGFR negative. Recently,
differences in growth factor expression between different sub-
types of human lung cancer have also been found (Soderdahl
et al., 1988). It is possible that this differential expression of
growth factors may, in part, explain the distinct biological
and clinical behaviour of histological subtypes of cancer.
We have also analysed the relationship of TGF mRNA
synthesis to tumour characteristics and disease-free survival
and overall survival of patients with breast cancer, but as yet
no relationship has been found in these relatively small
groups of patients. This does not mean that, with continued
follow-up, and with larger numbers of tumours, such a rela-
tionship may not eventually emerge. In fact, the data already
suggest that the possession of high levels of TGF beta
mRNA within a tumour confers some protection from
relapse, but this does not yet achieve statistical significance
(P = 0.1). Furthermore, higher levels of TGF beta mRNA
were shown to be weakly associated with the absence of
nodal metastases at presentation.
The studies presented here do not throw any light on the
site of synthesis of these peptides. It is likely that several or
all cell types present within these biopsies are capable of
TGF synthesis and it may be that information on the relative
synthetic capacity of various cell types will help to clarify
their role in tumour progression. To study this, we are
currently investigating the localisation of mRNA for TGF
alpha and TGF beta by in situ hybridisation.
We thank A. Ulirich for the gift of the cDNA probes. We also thank
U. Berger for assessment of immunocytochemistry and histological
tissue sections.
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